Amicus Therapeutics (FOLD) News Today $9.80 +0.07 (+0.72%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Moderate Buy" by AnalystsDecember 21 at 2:49 AM | americanbankingnews.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Given Average Rating of "Moderate Buy" by AnalystsShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine brokerages that are presently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendatiDecember 21 at 2:47 AM | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency ActDecember 18 at 1:09 PM | globenewswire.comJefferies Issues a Buy Rating on Amicus (FOLD)December 18 at 4:34 AM | markets.businessinsider.comAmicus Therapeutics (NASDAQ:FOLD) Rating Lowered to Hold at StockNews.comDecember 18 at 2:20 AM | americanbankingnews.comAmicus Therapeutics (NASDAQ:FOLD) Lowered to "Hold" Rating by StockNews.comStockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday.December 18 at 2:18 AM | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Holdings Lessened by Y Intercept Hong Kong LtdY Intercept Hong Kong Ltd cut its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 66.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 35,007 shares of the biophaDecember 17, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Stock Price Up 5.2% - Here's What HappenedAmicus Therapeutics (NASDAQ:FOLD) Shares Up 5.2% - Still a Buy?December 16, 2024 | marketbeat.comOrion Portfolio Solutions LLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Orion Portfolio Solutions LLC lessened its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 36.9% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 92,648 shares of the biopharmaceutical company's stock afteDecember 16, 2024 | marketbeat.comAmicus Therapeutics' (FOLD) Equal Weight Rating Reiterated at Morgan StanleyDecember 16, 2024 | americanbankingnews.comMorgan Stanley Downgrades Amicus Therapeutics (FOLD)December 14, 2024 | msn.comRetired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her SuspensionDecember 13, 2024 | globenewswire.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's WhyAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's What HappenedDecember 13, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Given "Equal Weight" Rating at Morgan StanleyMorgan Stanley restated an "equal weight" rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a report on Friday.December 13, 2024 | marketbeat.com65,786 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Neo Ivy Capital ManagementNeo Ivy Capital Management bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 65,786 shares of the biopharmaceutical company's sDecember 12, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Fmr LLCFmr LLC cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 22.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 802,056 shares of the biopharmaceutical company's stock after selliDecember 12, 2024 | marketbeat.comOld West Investment Management LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Old West Investment Management LLC boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 617.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,441 shares of the biopharDecember 11, 2024 | marketbeat.comStockNews.com Upgrades Amicus Therapeutics (NASDAQ:FOLD) to BuyStockNews.com upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday.December 10, 2024 | marketbeat.comWellington Management Group LLP Acquires 2,856,101 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Wellington Management Group LLP grew its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 13.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,964,044 shares of theDecember 9, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Point72 Asset Management L.P. bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,266,900 shareDecember 7, 2024 | marketbeat.comWhy Is Amicus Therapeutics (FOLD) Down 11.1% Since Last Earnings Report?December 7, 2024 | finance.yahoo.comPoint72 DIFC Ltd Makes New $704,000 Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Point72 DIFC Ltd acquired a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 65,925 shares of the biopharmaceutical company's stock, valued at approximately $704,000. A numbeDecember 6, 2024 | marketbeat.comJanus Henderson Group PLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Janus Henderson Group PLC decreased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 52.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,335,235 shDecember 6, 2024 | marketbeat.comRedmile Group LLC Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Redmile Group LLC lowered its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 22.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,246,592 shares of the biophaDecember 5, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Stock Position Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. raised its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 10.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,667,271 sharDecember 5, 2024 | marketbeat.comParkman Healthcare Partners LLC Acquires 102,855 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Parkman Healthcare Partners LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 20.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 605,318 shares of the biopharmaceutical cDecember 4, 2024 | marketbeat.comBradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockDecember 4, 2024 | insidertrades.comErste Asset Management GmbH Buys Shares of 116,850 Amicus Therapeutics, Inc. (NASDAQ:FOLD)Erste Asset Management GmbH bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 116,850 shares ofDecember 4, 2024 | marketbeat.comBNP Paribas Financial Markets Purchases 225,222 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)BNP Paribas Financial Markets boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 66.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 565,976 shares of the biopharmaceutical company'sDecember 4, 2024 | marketbeat.comNCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury TrialDecember 3, 2024 | globenewswire.comEdgestream Partners L.P. Buys 167,735 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Edgestream Partners L.P. grew its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 184.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 258,605 shares of the biopharmaceutical company's stock afterDecember 2, 2024 | marketbeat.com252,959 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Purchased by PDT Partners LLCPDT Partners LLC acquired a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 252,959 shares of the biopharmaceutical company's stock, valuedDecember 1, 2024 | marketbeat.comIntech Investment Management LLC Makes New Investment in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Intech Investment Management LLC bought a new stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 78,071 shares of the biopharmaceutical company's stock, valued at appNovember 29, 2024 | marketbeat.comAlgert Global LLC Has $2.77 Million Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Algert Global LLC lifted its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 192.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 259,160 shares of the biopharmaceutical compaNovember 27, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received an average recommendation of "Moderate Buy" from the nine brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rNovember 26, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Increases Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Massachusetts Financial Services Co. MA increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 4.6% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,160,027 shares of the biopharmaceutical company'sNovember 26, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Raises Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 51.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 222,934 shares of theNovember 26, 2024 | marketbeat.comPrincipal Financial Group Inc. Sells 213,538 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)Principal Financial Group Inc. decreased its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 88.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 27,275 shares of the biopharmaceutical company's stock after selling 213,538 sharesNovember 26, 2024 | marketbeat.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. reduced its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 44.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,258,208 shares of the biopharmaceNovember 20, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Should You Sell?Amicus Therapeutics (NASDAQ:FOLD) Shares Gap Down - Here's What HappenedNovember 19, 2024 | marketbeat.comAmicus Therapeutics (NASDAQ:FOLD) Upgraded by StockNews.com to Buy RatingStockNews.com upgraded shares of Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday.November 16, 2024 | marketbeat.comAvoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics IncNovember 14, 2024 | gurufocus.comAmicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLPGSA Capital Partners LLP boosted its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 163.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 133,800 shares of the biopharmaceuticalNovember 14, 2024 | marketbeat.comAmicus price target raised to $174 from $16 at JPMorganNovember 13, 2024 | markets.businessinsider.comThe Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 ExpertsNovember 13, 2024 | benzinga.comNCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial RightsNovember 12, 2024 | globenewswire.comAmicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00JPMorgan Chase & Co. increased their price target on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday.November 12, 2024 | marketbeat.comBuy Rating on Amicus Therapeutics Driven by Positive Revenue Outlook and Strategic Growth PlansNovember 10, 2024 | markets.businessinsider.comFiera Capital Corp Has $34.31 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)Fiera Capital Corp cut its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 39.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,212,561 shares of the biopharmaceutical company's stock afteNovember 9, 2024 | marketbeat.comBradley L. Campbell Sells 7,901 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) StockNovember 8, 2024 | insidertrades.com Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Could This Tiny Device Help You Make an Extra $30k a Year? (Ad)I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more than $9 trillion. That’s nearly 10 times more money than the market caps of Tesla… SpaceX… PayPal… Neuralink… and X… COMBINED. Click here to see the details because I believe a lot of people will get rich. FOLD Media Mentions By Week FOLD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. FOLD News Sentiment▼0.420.60▲Average Medical News Sentiment FOLD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. FOLD Articles This Week▼115▲FOLD Articles Average Week Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies EXAS News EXEL News RGEN News MDGL News HALO News IONS News ALKS News LGND News GERN News MNKD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:FOLD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTop Picks for Trump’s Pro-Crypto AmericaCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FOLD Stock Alerts